LGND - Ligand Pharmaceuticals Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
90.07
-0.32 (-0.35%)
As of 10:33AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close90.39
Open90.07
Bid90.10 x 1200
Ask90.32 x 1200
Day's Range89.65 - 90.87
52 Week Range84.45 - 130.50
Volume25,917
Avg. Volume323,056
Market Cap1.582B
Beta (5Y Monthly)1.24
PE Ratio (TTM)3.18
EPS (TTM)28.29
Earnings DateFeb 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 30, 2010
1y Target Est196.20
  • Business Wire

    Ligand Enters into OmniAb® Platform License Agreement with Pandion Therapeutics

    Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb license agreement with Pandion Therapeutics. Under the agreement, Pandion will be able to use Ligand’s full OmniAb antibody discovery platform which includes OmniRat®, OmniFlic®, OmniMouse®, OmniChicken® and OmniClic™. OmniAb is licensed to over 40 corporate partners globally, and this deal with Pandion adds to a growing portfolio of OmniAb discovery and clinical development programs. Pandion will pay Ligand an up-front platform access fee, development and regulatory milestone payments, and potential royalties on sales of marketed products.

  • Top Biotech Stocks for Q1 2020
    Investopedia

    Top Biotech Stocks for Q1 2020

    These are the biotechnology stocks with the best value, fastest growth, and most momentum for Q1 2020.

  • Business Wire

    Ligand to Report 2019 Fourth Quarter and Full Year Financial Results on February 6th

    Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report 2019 fourth quarter and full year financial results on February 6, 2020. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.

  • Does Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Have A High Beta?
    Simply Wall St.

    Does Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Have A High Beta?

    Anyone researching Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) might want to consider the historical volatility...

  • LGND vs. ALKS: Which Stock Is the Better Value Option?
    Zacks

    LGND vs. ALKS: Which Stock Is the Better Value Option?

    LGND vs. ALKS: Which Stock Is the Better Value Option?

  • Business Wire

    Two Ligand Pharmaceuticals Board Members Recognized as 2019 Most Influential Corporate Directors by WomenInc. Magazine

    Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that two members of its Board of Directors, Nancy Gray and Sarah Boyce, have been named to WomenInc. magazine’s 2019 Most Influential Corporate Directors list.

  • Is Ligand Pharmaceuticals Inc. (LGND) A Good Stock To Buy ?
    Insider Monkey

    Is Ligand Pharmaceuticals Inc. (LGND) A Good Stock To Buy ?

    Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

  • Benzinga

    12 Biotech Stocks Primed For A Short Squeeze

    Biotech investment is fraught with risk. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts. These binary events , however, provide an opportunity for making ...

  • Why Is Ligand (LGND) Up 5.3% Since Last Earnings Report?
    Zacks

    Why Is Ligand (LGND) Up 5.3% Since Last Earnings Report?

    Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Business Wire

    Ligand Enters into Worldwide OmniAb® Platform License Agreement with Sanofi

    Ligand Pharmaceuticals Incorporated (LGND) announces it has entered into a worldwide OmniAb license agreement with Sanofi. Under the agreement, Sanofi will be able to use Ligand’s full OmniAb antibody discovery platform which includes OmniRat®, OmniFlic®, OmniMouse®, OmniChicken® and OmniClic™ in addition to Ligand’s patented antigen technology. OmniAb is licensed to over 40 corporate partners globally, and this deal with Sanofi adds to a growing portfolio of OmniAb discovery and clinical development programs with global fully-integrated pharmaceutical companies.

  • Thomson Reuters StreetEvents

    Edited Transcript of LGND earnings conference call or presentation 5-Nov-19 9:30pm GMT

    Q3 2019 Ligand Pharmaceuticals Inc Earnings Call

  • Business Wire

    Ligand Pharmaceuticals Ranked in Deloitte’s 2019 Technology Fast 500™

    Ligand Pharmaceuticals Incorporated (LGND) today announced it ranked in Deloitte’s Technology Fast 500™, a listing of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America now in its 25th year. “This is the third time Ligand has been included in the Technology Fast 500, and we are very pleased once again to be recognized by Deloitte for our rapid revenue growth,” said John Higgins, Chief Executive Officer of Ligand.

  • Business Wire

    Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol

    Presentation at the American Society of Nephrology Kidney Week 2019

  • Business Wire

    Ligand to Participate in the Stephens 2019 Nashville Investment Conference

    Ligand Pharmaceuticals Incorporated (LGND) announces that the company is scheduled to participate in the Stephens 2019 Nashville Investment Conference in Nashville, Tennessee. Matt Korenberg, CFO will attend for Ligand. Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines.

  • Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down
    Zacks

    Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down

    Ligand (LGND) reports lower-than-expected third-quarter 2019 earnings. It also lowers outlook for 2019 earnings. However, revenues were better than expected.

  • Talem Therapeutics accesses the OmniAb® platform from Ligand Pharmaceuticals
    CNW Group

    Talem Therapeutics accesses the OmniAb® platform from Ligand Pharmaceuticals

    VICTORIA , Nov. 5, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces that Talem Therapeutics, a wholly-owned subsidiary, has entered into a worldwide OmniAb® platform license agreement with Ligand Pharmaceuticals (LGND). This license enables Talem to access Ligand's unique OmniAb platform for use with Talem's leading antibody discovery capabilities. Under the license, Talem has the right to develop and partner fully human antibodies in OmniRat®, OmniFlic®, OmniMouse®, OmniChicken®, and OmniClic™.

  • Business Wire

    Ligand Reports Third Quarter 2019 Financial Results

    Conference Call Begins at 4:30 p.m. Eastern Time Today

  • Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out for

    Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Is Ligand Pharmaceuticals Inc. (LGND) Going To Burn These Hedge Funds ?
    Insider Monkey

    Is Ligand Pharmaceuticals Inc. (LGND) Going To Burn These Hedge Funds ?

    Is Ligand Pharmaceuticals Inc. (NASDAQ:LGND) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their consensus stock picks […]

  • Business Wire

    Ligand to Report Third Quarter 2019 Results on November 5th

    Ligand Pharmaceuticals Incorporated announced today plans to report third quarter 2019 financial results on November 5, 2019. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.

  • Business Wire

    Ligand Appoints Pharmaceutical Executive Sarah Boyce to its Board of Directors

    Ligand Pharmaceuticals Incorporated (LGND) (“Ligand” or “the Company”) announces the appointment of Sarah Boyce to the Company's Board of Directors, effective today. Ms. Boyce currently serves as President and CEO of Avidity Biosciences, Inc., a privately held biotechnology company pioneering the use of antibody-oligonucleotide conjugates (AOC™) to treat rare muscle disorders and other serious diseases. Ms. Boyce's appointment increases the number of Ligand directors to nine.

  • Who Has Been Buying Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares?
    Simply Wall St.

    Who Has Been Buying Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

  • CNW Group

    ImmunoPrecise Strengthens Board of Directors with Antibody Business Leader, Brian Lundstrom

    VICTORIA , Oct. 3, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced the appointment of Brian Lundstrom to the company's Board of Directors. Trained in immunology and international business, Mr. Lundstrom has over 30 years' experience from mostly publicly traded companies with a focus on antibody therapeutics.

  • GlobeNewswire

    Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer

    Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the precision medicine metastatic breast cancer arena, today announced the enrollment and dosing of the first patient into a Phase 2 clinical trial of its lead investigational drug, lasofoxifene. The open-label, randomized, multi-center Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE, NCT03781063) study will assess the efficacy of oral lasofoxifene versus intramuscular fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic estrogen receptor-positive (ER+)/HER2- breast cancer with an ESR1 mutation and progression-free survival as the primary endpoint.

  • Ligand (LGND) Surges: Stock Moves 6.3% Higher
    Zacks

    Ligand (LGND) Surges: Stock Moves 6.3% Higher

    Ligand (LGND) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.